Stockholm - Delayed Quote SEK

EQL Pharma AB (EQL.ST)

Compare
49.50 -1.90 (-3.70%)
At close: 5:21 PM GMT+2
Loading Chart for EQL.ST
DELL
  • Previous Close 51.40
  • Open 51.40
  • Bid 49.80 x --
  • Ask 50.00 x --
  • Day's Range 49.50 - 51.40
  • 52 Week Range 24.70 - 55.00
  • Volume 10,866
  • Avg. Volume 21,594
  • Market Cap (intraday) 1.439B
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) 65.13
  • EPS (TTM) 0.76
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

www.eqlpharma.com

21

Full Time Employees

March 31

Fiscal Year Ends

Recent News: EQL.ST

Performance Overview: EQL.ST

Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EQL.ST
48.20%
OMX Stockholm 30 Index
6.69%

1-Year Return

EQL.ST
60.71%
OMX Stockholm 30 Index
10.16%

3-Year Return

EQL.ST
33.78%
OMX Stockholm 30 Index
11.90%

5-Year Return

EQL.ST
309.09%
OMX Stockholm 30 Index
60.95%

Compare To: EQL.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EQL.ST

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    1.49B

  • Enterprise Value

    1.60B

  • Trailing P/E

    67.63

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.80

  • Price/Book (mrq)

    8.41

  • Enterprise Value/Revenue

    6.06

  • Enterprise Value/EBITDA

    46.66

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.60%

  • Return on Assets (ttm)

    6.18%

  • Return on Equity (ttm)

    13.66%

  • Revenue (ttm)

    264.17M

  • Net Income Avi to Common (ttm)

    22.7M

  • Diluted EPS (ttm)

    0.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    20.47M

  • Total Debt/Equity (mrq)

    67.57%

  • Levered Free Cash Flow (ttm)

    -97.81M

Research Analysis: EQL.ST

Company Insights: EQL.ST

Research Reports: EQL.ST

People Also Watch